Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01518309 · ClinicalTrials.gov registry record · Phase 2
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
A Phase 2 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT01518309: Completed Phase 2 study, sponsored by ACADIA Pharmaceuticals.
NCT01518309 is a Phase 2 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 39 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01518309, a Phase 2 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
Primary Outcome
Number (%) of patients with drug-related treatment-emergent AEs
Interventions
- DRUG pimavanserin tartrate (ACP-103)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2004-11-17 |
| Est. Completion | 2013-05-02 |
| Phase | Phase 2 |
What the finished NCT01518309 record still lists
NCT01518309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 1 intervention - of which pimavanserin tartrate (ACP-103) is the first listed.
NCT01518309 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01518309 about?
NCT01518309 is a clinical study titled "An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients". This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
What is the current status of trial NCT01518309?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2004-11-17. Estimated completion is 2013-05-02.
What interventions are being tested in trial NCT01518309?
The interventions under investigation include: pimavanserin tartrate (ACP-103) (DRUG).
Who is sponsoring clinical trial NCT01518309?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01518309's enrollment target sits among peer trials
39 1459th of 2000 higher than 534 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI